Clinical Trial Update: A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating crizotinib in East Asian patients with ALK-positive advanced non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Crizotinib (crizotinib)

Snippet

Sponsor: Pfizer | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN